In vitro combination of antifungal drugs with tacrolimus (FK506) holds promise against clinical Candida species, including Candida auris
© The Author(s) 2023. Published by Oxford University Press on behalf of The International Society for Human and Animal Mycology..
In vitro interactions between tacrolimus, a calcineurin inhibitor, and fluconazole, itraconazole, caspofungin, or anidulafungin were evaluated against Candida auris, C. albicans, C. parapsilosis, and C. glabrata (each five strains). Tacrolimus-itraconazole, tacrolimus-caspofungin, and tacrolimus-fluconazole combinations resulted in synergistic interactions against 95%, 90%, and 60% of Candida isolates, respectively. However, tacrolimus-anidulafungin resulted in only a 35% synergistic effect. A combination of tacrolimus and itraconazole was most potent with synergy against 100% of C. auris, C. parapsilosis, and C. glabrata isolates. Of note, no antagonistic interaction was found.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:61 |
|---|---|
| Enthalten in: |
Medical mycology - 61(2023), 7 vom: 06. Juli |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Khodavaisy, Sadegh [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 26.07.2023 Date Revised 26.07.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1093/mmy/myad069 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM359387284 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM359387284 | ||
| 003 | DE-627 | ||
| 005 | 20231226080748.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/mmy/myad069 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1197.xml |
| 035 | |a (DE-627)NLM359387284 | ||
| 035 | |a (NLM)37437917 | ||
| 035 | |a (PII)myad069 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Khodavaisy, Sadegh |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a In vitro combination of antifungal drugs with tacrolimus (FK506) holds promise against clinical Candida species, including Candida auris |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 26.07.2023 | ||
| 500 | |a Date Revised 26.07.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © The Author(s) 2023. Published by Oxford University Press on behalf of The International Society for Human and Animal Mycology. | ||
| 520 | |a In vitro interactions between tacrolimus, a calcineurin inhibitor, and fluconazole, itraconazole, caspofungin, or anidulafungin were evaluated against Candida auris, C. albicans, C. parapsilosis, and C. glabrata (each five strains). Tacrolimus-itraconazole, tacrolimus-caspofungin, and tacrolimus-fluconazole combinations resulted in synergistic interactions against 95%, 90%, and 60% of Candida isolates, respectively. However, tacrolimus-anidulafungin resulted in only a 35% synergistic effect. A combination of tacrolimus and itraconazole was most potent with synergy against 100% of C. auris, C. parapsilosis, and C. glabrata isolates. Of note, no antagonistic interaction was found | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Candida auris | |
| 650 | 4 | |a FK506 | |
| 650 | 4 | |a calcineurin | |
| 650 | 4 | |a drug interactions | |
| 650 | 4 | |a drug resistance | |
| 650 | 4 | |a tacrolimus | |
| 650 | 7 | |a Antifungal Agents |2 NLM | |
| 650 | 7 | |a Tacrolimus |2 NLM | |
| 650 | 7 | |a WM0HAQ4WNM |2 NLM | |
| 650 | 7 | |a Fluconazole |2 NLM | |
| 650 | 7 | |a 8VZV102JFY |2 NLM | |
| 650 | 7 | |a Caspofungin |2 NLM | |
| 650 | 7 | |a F0XDI6ZL63 |2 NLM | |
| 650 | 7 | |a Anidulafungin |2 NLM | |
| 650 | 7 | |a 9HLM53094I |2 NLM | |
| 650 | 7 | |a Itraconazole |2 NLM | |
| 650 | 7 | |a 304NUG5GF4 |2 NLM | |
| 650 | 7 | |a Echinocandins |2 NLM | |
| 700 | 1 | |a Gharehbolagh, Sanaz Aghaei |e verfasserin |4 aut | |
| 700 | 1 | |a Abdorahimi, Mahsa |e verfasserin |4 aut | |
| 700 | 1 | |a Rezaie, Sara |e verfasserin |4 aut | |
| 700 | 1 | |a Ahmadikia, Kazem |e verfasserin |4 aut | |
| 700 | 1 | |a Badali, Hamid |e verfasserin |4 aut | |
| 700 | 1 | |a Meis, Jacques F |e verfasserin |4 aut | |
| 700 | 1 | |a Mahmoudi, Shahram |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Medical mycology |d 1997 |g 61(2023), 7 vom: 06. Juli |w (DE-627)NLM097151785 |x 1460-2709 |7 nnns |
| 773 | 1 | 8 | |g volume:61 |g year:2023 |g number:7 |g day:06 |g month:07 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/mmy/myad069 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 61 |j 2023 |e 7 |b 06 |c 07 | ||